Rezolute (RZLT) Stock Forecast & Price Target

Rezolute Inc. has demonstrated significant progress in developing its therapy, ersodetug, which has led to substantial improvements in hypoglycemia management and has shown a favorable safety profile in clinical trials. With up to 70% of congenital hyperinsulinism patients unresponsive to standard of care (SoC), there exists a considerable market opportunity for Rezolute to address this unmet need with its innovative treatment options. The potential for a broader commercial opportunity, with indications beyond the implied base case of 1,500 patients, underscores the positive growth prospects for Rezolute's stock as it advances its pipeline toward successful regulatory outcomes.

Rezolute Inc reported a net loss of $24.4 million for the fourth quarter of 2025, which was slightly better than the consensus estimate of $25.9 million, but still reflects significant financial challenges faced by the company. For the full fiscal year 2025, Rezolute is projected to incur a net loss of $74.4 million, better than the consensus estimate of $95 million, indicating ongoing operational losses and financial strain. Furthermore, potential delays in the regulatory approval process due to FDA staffing issues could hinder the company's ability to bring its therapies to market, exacerbating its financial outlook.